CHICAGO – Improved radiotherapy techniques have made it possible for men to achieve reductions in PSA to below detectable levels following radiation treatment for prostate cancer, according to new ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...

Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial PURPOSE: To develop evidence-based guidelines for (1) prostate re-biopsy after radiation and ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

The success rate of salvage radiation after prostatectomy differs by patients’ PSA. Only a subset of patients with biochemically recurrent prostate cancer after radical prostatectomy (RP) will develop ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

“As a two-time prostate cancer survivor, I enjoy today as if it will be my last,” Jesse said. “I engage every man I meet ...